Next 10 |
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for ACAD on June 26, 2024 04:09PM ET. The previous analyst recommendation was Buy. ACAD was trading at $15.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
2024-06-26 17:00:07 ET Keith Tapper from BMO Capital issued a price target of $31.00 for ACAD on 2024-06-26 16:09:00. The adjusted price target was set to $31.00. At the time of the announcement, ACAD was trading at $15.5. The overall price target consensus is at $26.25 ...
2024-06-23 11:32:35 ET Summary Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trad...
2024-06-19 14:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoin...
2024-06-14 12:10:53 ET Summary Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a P...
2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...
2024-06-09 14:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-05 23:46:37 ET Summary ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 milli...
2024-05-29 10:01:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are some pharma stocks to sell in May this year. These companies have been grappling with various issues. These include pipeline setbacks, increasing competition, and regulatory hurdles. ...
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
NASDAQ Market:
ACADIA Pharmaceuticals Inc. Website:
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for ACAD on June 26, 2024 04:09PM ET. The previous analyst recommendation was Buy. ACAD was trading at $15.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
2024-06-26 17:00:07 ET Keith Tapper from BMO Capital issued a price target of $31.00 for ACAD on 2024-06-26 16:09:00. The adjusted price target was set to $31.00. At the time of the announcement, ACAD was trading at $15.5. The overall price target consensus is at $26.25 ...
2024-06-19 14:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...